Latest news with #TanushreeJain
Business Insider
11 hours ago
- Business
- Business Insider
Petra Capital Sticks to Their Buy Rating for Artrya Limited (AYA)
In a report released yesterday, Tanushree Jain from Petra Capital maintained a Buy rating on Artrya Limited (AYA – Research Report), with a price target of A$2.81. The company's shares opened today at A$0.67. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jain covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Dimerix Limited, and Artrya Limited. According to TipRanks, Jain has an average return of 23.6% and a 44.12% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Artrya Limited with a A$2.81 average price target. The company has a one-year high of A$1.04 and a one-year low of A$0.20. Currently, Artrya Limited has an average volume of 250.8K.
Business Insider
19-05-2025
- Business
- Business Insider
Petra Capital Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)
In a report released on May 16, Tanushree Jain from Petra Capital maintained a Buy rating on Neuren Pharmaceuticals Limited (NURPF – Research Report), with a price target of A$31.45. The company's shares closed last Monday at $8.14. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Jain is ranked #778 out of 9519 analysts. Currently, the analyst consensus on Neuren Pharmaceuticals Limited is a Strong Buy with an average price target of $17.11, an 110.25% upside from current levels. In a report released on May 9, Bell Potter also maintained a Buy rating on the stock with a A$20.00 price target. NURPF market cap is currently $1.08B and has a P/E ratio of 11.50.
Business Insider
07-05-2025
- Business
- Business Insider
Petra Capital Keeps Their Buy Rating on Dimerix Limited (DXB)
In a report released yesterday, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with a price target of A$1.58. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Jain is a 5-star analyst with an average return of 33.0% and a 47.54% success rate. Currently, the analyst consensus on Dimerix Limited is a Moderate Buy with an average price target of A$1.28. DXB market cap is currently A$422.8M and has a P/E ratio of -15.73.
